Bristol-Myers Squibb and Merck joint statement on FDA Advisory Committee vote on Pargluva (muraglitazar), an investigational oral treatment for Type 2 diabetes.

(From Chemical Business NewsBase - Press Release)

Bristol-Myers Squibb and Merck & Co Inc jointly announced that the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted to recommend approval of Pargluva (muraglitazar), the companies' investigational oral medicine for the treatment of Type 2 diabetes, for use as monotherapy and in combination with metformin. The committee voted not to recommend its use in combination with a sulfonylurea. Bristol-Myers Squibb researchers presented the available pre-clinical and clinical data to support the benefit-risk profile of Pargluva and reviewed a comprehensive pharmacovigilance plan …